RPS19 has been identified as the first gene associated to Diamond-Blackfan anemia (DBA), a rare congenital hypoplastic anemia that includes variable physical malformations. It is mutated in about 25% of the patients although doubts remain as to whether DBA clinical phenotype depends on the ribosomal function of RPS19 or on an extra-ribosomal role or on both. RPS19 mRNAs with mutations which introduce premature stop codons or eliminate it are rapidly turned over by the surveillance mechanisms possibly causing a decrease in the RPS19 protein level. A decrease in RPS19 level has been shown to cause a defect in the maturation of 18S rRNA. Less clear is the effect of missense mutations in RPS19. With the aim of analyzing the functional features of mutated RPS19, we prepared cDNA constructs expressing RPS19 containing 11 missense mutations and a trinucleotide insertion found in DBA patients. After transfection we analyzed the following properties of the mutated proteins: i) protein stability, ii) subcellular localization, iii) assembly into ribosomes. Our results indicate that some RPS19 mutations alter the capacity of the protein to localize in nucleolar structure and these mutated RPS19 are very unstable. Moreover none of the mutated RPS19 analyzed in this study, including those proteins that appear localized into the nucleolus, is able to be assembled into mature ribosome.
INTRODUCTION
Diamond-Blackfan anemia (DBA, MIM#s 105650, 205900) is the first human disease associated to mutations in a ribosomal structural protein. In fact, following the finding that ribosomal protein (RP) S19 (MIM #603474) is involved in this disorder (1) , causal mutations have been characterised in 24% of 217 DBA patients (2-4). The major clinical feature of DBA is a congenital erythroblastopenia characterized by absent or decreased erythroid precursors. Approximately 30% of affected children present a variety of associated physical anomalies, which are predominantly craniofacial but also include thumb, cardiac, and urogenital malformations (5, 6) . Clinical features associated with the mutations in the RPS19 gene show a wide range of variability, even for the same mutation in the same family (3) . The lack of correlation between clinical presentation and genotype suggests that other factors may modulate the expression of the genetic defect.
Since all DBA patients with RPS19 mutations appear to have a normal allele, it can be assumed that the disease is caused by haploinsufficiency and/or dominant negative effect of the mutated proteins.
It is not clear how alterations in the synthesis and/or function of a ribosomal protein could influence normal development. Possible hypotheses are: 1) ribosome function is critical during erythropoiesis and any decrease of activity could compromise the process; 2) RPS19 has an extraribosomal specific function necessary for erythroid differentiation. Alternatively (or in addition) RPS19 could play a specific role within the ribosome: for example i) it could be a target for ribosome-binding factors or ii) it could be necessary for the proper translation of particular mRNAs (7) . An extraribosomal role of RPS19 dimer as monocyte chemotactic factor has been described by Yamamoto and colleagues (8). However, the physiological relevance of this finding is not clear and we have never observed the dimer in the cultured cells analyzed. On the other hand, the recent finding that about 2% of DBA cases show mutations in the RPS24 gene (9) supports the hypothesis of an alteration of a ribosomal function in the disease, although such function could still be both general and hemopoiesis-specific. Consistent with the involvement of ribosome synthesis in DBA, we have recently defined the RPS19 interactome and showed that it interacts with multiple proteins involved in ribosome biogenesis and function (10) . Moreover, gene products mutated in some bone marrow failure syndromes are predicted to be involved in ribosome biogenesis (11) . That the general translation efficiency plays a role in DBA is also suggested by the observation that lymphocytes from DBA patients with or without RPS19 mutations have reduced translation activity (12) . We have observed an interaction between RPS19 and PIM1 (13), a serine threonine kinase controlled by erythroid growth factors known to phosphorylate translational regulators (14, 15) .
The attempt to generate an animal model for studying DBA produced puzzling results. In fact in mice, complete loss of RPS19 results in early embryonic lethality whereas RPS19+/-mice are viable and without major abnormalities, even in the hematopoietic system (16) . The authors propose that the loss of one RPS19 allele is fully compensated for at the mRNA level with preservation of erythropoiesis. Suppression of erythroid differentiation and cell growth has been observed in a human leukemic cell line expressing siRNA against RPS19 (17) . This suggests that RPS19 may function in the regulation of cell proliferation and differentiation. The specific role of RPS19 in ribosome synthesis and function has been recently addressed in yeast (18, 19) . Both reports showed that the deletion of one copy of the two RPS19 genes causes a defect in the maturation of 18S rRNA. A similar alteration has been shown in cells from DBA patients and in cell lines depleted of RPS19 by specific siRNA (17, 20, 21) . How this alteration correlates with the clinical features of DBA remains unclear, however.
On the basis of the results obtained by us and by other laboratories (22, 23) , RPS19 mutations found in DBA can be divided into (at least) two groups: i) mutations that cause a decrease in the amount of RPS19 mRNA, that is insertions, deletions, splice site and nonsense mutations which alter the position of the termination codon and therefore cause mRNA degradation by surveillance mechanisms; ii) missense mutations which presumably affect the function(s) of the protein. The first class of mutations is likely to cause a decrease in the synthesis of the protein and, at least in some cases, this is associated to alteration of rRNA maturation (21 cause a defect at different steps in the process of ribosome assembly. Alternatively, the altered protein could be integrated into the ribosomal subunit and generate malfunctioning in the translation process. It has been shown that at least two missense mutations can alter nucleolar localization of RPS19 (24) . However, other mutations do not cause this alteration; therefore it is not clear if or how much mutated RPS19 can proceed in the pathway of ribosome biogenesis. To investigate this issue, we prepared cDNA constructs expressing RPS19 which contains 11 missense mutations and one insertion found in DBA patients. We used these constructs in transfection experiments into cultured cells to study the functional capacity of the differently mutated RPS19. The results indicate that the mutations analyzed can affect protein stability and nucleolar localization in different ways. In all cases, however, the altered proteins fail to be assembled into ribosome.
RESULTS

Expression and stability of mutated RPS19
Eleven missense mutations and one trinucleotide insertion after codon 19 identified in DBA patients were introduced into Flag-tagged RPS19 cDNA by site-directed mutagenesis. The cDNAs were then inserted into a eukaryotic expression vector and used in transient transfection experiments into HEK293 cells. The expression of the mutated RPS19 proteins, distinguishable from the endogenous by size, was monitored by western blot analysis using Flag-specific and RPS19-specific monoclonal antibodies (mAb). As a control for transfection efficiency we used the product of the neomycin phosphotransferase gene (NPT) present in the cloning vector (pcDNA3) and therefore expressed at a level proportional to the amount of plasmids inserted into the cells. An example of the western analysis is reported in Fig. 1A . The intensity of the signals show an evident variability not justified by transfection efficiency. In particular the mutated RPS19 proteins V15F, L18P, A57P, A61E, G127E, INS are barely detectable (indicated by an asterisk) whereas the remaining mutations show an intensity comparable to the unmutated (WT) RPS19 protein used as control. The difference in the level of the transfected Flagged RPS19 proteins could be due to a differential stability of the mRNAs or, more likely, to a differential stability of the mutated RPS19 proteins. To investigate on the turnover of the mutated RPS19 we isolated HEK293 clones stably expressing Flag-tagged proteins. Surprisingly, compared to the levels of WT Flag-RPS19 those of mutated Flag-RPS19 were very low in all the clones analyzed (at least three for each cDNA construct, data not shown). To assess whether the level of the transfected proteins was affected by rapid turnover, clones stably expressing R62W and R101H and WT RPS19 proteins respectively, were treated with the translation inhibitor cycloheximide and analyzed by western blot with the mAb specific for RPS19. The mAb can detect both endogenous and Flag-tagged transfected RPS19, the two of them being distinguishable by size. The results of this analysis (shown in Fig. 1B) indicate that both mutated Flag-RPS19 (R62W and R101H) are degraded more rapidly compared to unmutated Flag-RPS19 which exhibits stability comparable to the endogenous RPS19. Further confirmation of the increased turnover of the mutated RPS19 was obtained by treating the cells with the proteasome inhibitor MG132. In this case, as reported in Fig. 1C , the signal relative to R62W and R101H mutated RPS19 shows a clear increase compared to WT Flag-RPS19 and endogenous RPS19. This again suggests that the two mutated proteins are degraded (at least partly by the proteasome) more rapidly than WT Flag-RPS19 is.
Subcellular localization
To investigate on the intracellular localization of the mutated RPS19 proteins the same cDNA constructs described in the previous paragraph were used in transient transfection experiments in HeLa cells. The cells were then analyzed by immunofluorescence microscopy using monoclonal antibodies against the Flag epitope. As a marker for nucleolar localization we used a polyclonal antibody against nucleolin (C23). As shown in Fig This could indicate that due to both overexpression and/or the presence of the GFP tag, the transfected RPS19 is not correctly assembled into ribosomes. In the same study, the authors report a faint signal of endogenous RPS19 in the cytoplasm, in contrast to what we found (Fig. 2B) . The discrepancy could be due to the fact that the antibody used by Da Costa et al. does not recognize RPS19 assembled into the ribosome which is the form of RPS19 predominant in the cytoplasm.
Ribosome association
The other property of the mutated Flag-RPS19 proteins we analyzed is their capability to be assembled into functional or aberrant ribosomal subunits. WT, is reported in Fig. 3A . Endogenous RPS19 is present, as expected, in all the ribosomal fractions including 40S subunits (fraction 1 to 9) whereas S6K1 is visible only in light cytosolic fractions (fractions 10 to 12). The Flag-tagged WT RPS19 protein is mostly present in the free cytoplasmic fractions but can also be clearly seen to be associated to ribosomes, including polysomes. The experiment was repeated for all RPS19 constructs and, as shown in Fig. 3B , produced essentially the same result: Mutated RPS19 is never found associated to ribosomes. To confirm this observation we tried a slightly different technique, namely fractionation of the cytoplasmic extracts by 100,000 g centrifugation in a ribosomal pellet (including 40S ribosomal subunits) and cytosolic supernatant. The results, reported in Fig. 3C , again show that part of Flag-RPS19 WT can be found in the pellet whereas all mutated RPS19 analyzed appear unable to associate with ribosomes. We then analyzed the HEK293 cell lines stably expressing WT Flag-RPS19 cDNAs and the mutated RPS19, A57P, R62W (not shown), R101H and G127E. The cells were also treated with the proteasome inhibitor MG132 to induce an increase in protein level. The results, reported in Fig 4, show that the stably expressed WT Flag-RPS19 is mostly present in the ribosomal pellet. By contrast, the mutated proteins, of which only R101H and G127E are shown as an example, are never present in the pellet even in cells treated with the inhibitor.
Our analysis of the ribosomal association of the mutated RPS19 showed that part of the WT and all the mutated Flag-RPS19 proteins are not assembled into ribosomes and are visible as putative free cytoplasmic proteins. However, this is not consistent with the immunomicroscopy analysis which showed no cytoplasmic staining for the Flag-RPS19 proteins. Therefore we hypothesized that the experimental conditions used during the preparation of the cytoplasmic extracts were too drastic and caused the leakage of material from the nucleus. To verify the hypothesis we repeated the experiment with the cells transiently expressing WT Flag-RPS19 by using milder conditions to prepare cytoplasmic extracts. This time, as shown in Fig 5, the amount of protein present in the supernatant was clearly lower than in the previous procedure. This suggests that most of the Flag-RPS19 which appeared as free protein in the previous analyses is probably present in the nucleus.
DISCUSSION
Recent publications have provided support to the hypothesis that DBA may be caused by alteration of a ribosomal function (9, 11) . Ribosome biogenesis is a complex process that requires the transfer of multiple proteins in and out of the nucleolus. Maturation of the ribosomal RNA (rRNA) and its assembly into ribosomal subunits involves more than 150 accessory proteins and about as many small nucleolar ribonucleoprotein particles (25, 26) . The role of the RPs in the process is mostly obscure. A recent systematic analysis of yeast RPs of the small subunit revealed that different RPs control distinct steps of nuclear and cytoplasmic pre-18S rRNA processing (18) . Depletion of RPS19, as observed also by Leger-Silvestre et al. (19) , causes a defect in 18S rRNA processing in the nucleus and blocks maturation of 40S subunits. Similar defects have been observed in human cells after RPS19 knock-down by siRNA (21, 27) . Therefore mutations in the RPS19 gene which protein stability showed a correlation with the immunofluorescence localization data. In fact all the more stable RPS19 proteins (including the WT) showed a clear nucleolar localization whereas the less stable ones were not detectable in the nucleoli (Tab. 1). Although the correlation between the two analyses is evident, the possible causal relationship between the two observations is less clear.
In fact we favor the hypothesis that the lack of nucleolar localization, due to the incapability of mutated RPS19 to interact with other components of the ribosome biogenesis pathway, would cause rapid degradation of the protein. In the case of nucleolar localization the interaction with at least some component of the ribosome biosynthesis machinery would cause a partial stabilization of the protein. However, it could also be that it is the stability of the protein which determines if they are visible in the nucleolus or not. The maximum stability of the transfected RPS19 (comparable to the endogenous RPS19) is observed only when the transfected protein successfully participates in ribosome assembly and is exported into the cytoplasm. This is verified only in the case of WT Flag-RPS19. In fact our analysis by two different experimental approaches of transient and stable transfectants failed to detect that any of the mutated RPS19 analyzed was associated to ribosomes or 40S subunits. Even the stabilization of the mutated proteins by proteasome inhibitor did not cause an increase of the signal in the ribosomal fractions above the detection level. In the same experimental setup we were able to show that, partially in transient and more completely in stable transfection, the WT Flag-RPS19 is associated to actively translating ribosomes.
In conclusion all the RPS19 mutations analyzed in this study cause a decrease of protein stability, with some mutations having a stronger effect. Some of the mutated RPS19 proteins appear localized in the nucleolus whereas the others apparently fail to remain associated with nucleolar structures (see table) . The failure of the V15F and G127E mutated proteins to localize in the nucleolus is in agreement with previous observations by Da Costa et al. (24) . In such study the authors suggest that the two mutations identify nucleolar localization signals. Our observations may point out to further signals, as indicated by the failed localization of mutated proteins A57P, A61E and INS. However we think that nucleolar localization depends on the interaction of RPS19 with other nucleolar components. Mutations affecting such interactions would cause a failure of the mutated proteins to be retained in the nucleolus. Interestingly the mutants which are not visible in the nucleolus appear to have a much shorter half-life. None of the mutated RPS19 is able to be assembled into mature ribosome, not even those proteins which appear localized inside the nucleolus.
These results allow RPS19 missense mutations to be grouped into two classes: a) mutations which cause a failure in nucleolar localization and, possibly as a consequence, a drastic decrease in protein half-life. Moreover, the mutated proteins are not detectable in association with ribosomes b) mutations which allow RPS19 to associate with nucleolar structures but not to be assembled into ribosome. In this case the half-life of the proteins, although shorter than WT RPS19 is, may be longer than that of the mutated RPS19 of the first class.
Implications of our findings for the understanding of the molecular mechanism of DBA should be considered with caution. In fact our experimental setup consists in overexpression of tagged RPS19 constructs in standard cell lines (HEK293, HeLa). Therefore we cannot assume that the results obtained are also valid in hematopoietic cells. However, considering the constitutive and ubiquitous expression of RPS19, it could be that the effect of mutations on the function of the protein is the same in all cell types. If this is case, our results indicate that missense mutations, in addition to mutations altering RPS19 mRNA level, cause insufficiency of RPS19 in hematopoietic cell of DBA patients. Therefore the variability of clinical symptoms associated to the disease cannot be due to a differential effect of the mutations but, possibly, to the effect of unknown modifier factor(s).
Moreover, our findings highlight the risk of failure in attempting a rescue of the DBA clinical symptoms by inducing overexpression or stabilization of mutated proteins, a method that has been proposed for other diseases (28) . In fact, it is highly likely that mutated RPS19 will never be assembled into functional ribosomes. Transfected cell clones were selected in the presence of 800 μg/ml of G418 (Invitrogen).
MATERIALS AND METHODS
Cell culture and transfection
For translation inhibition cells were treated with 30 μg/ml of cycloheximide. For proteasome inhibition cells were treated with 10μM MG132 (Sigma) for 12h.
DNA constructs
RPS19 expression plasmids were constructed by inserting RT-PCR products into pcDNA3 (Invitrogen, Milan, Italy) downstream from the sequence coding for the FLAG-tag (pFLAG-RPS).
The RPS19 natural mutants R62Q, R62W, R101H and in-frame insertion (53_54insAGA, which is expected to inserts an arginine after residue 18) were prepared by RT-PCR from peripheral blood lymphocytes of DBA patients after informed consent. The following primers, that include EcoRI and XhoI restriction sites, were used:
Reverse 5'-GTCTCGAGCCAGCATGGTTTGTTCTAATG -3'
All the other mutants were obtained by PCR-dependent mutagenesis using RPS19 wild-type.
Western analysis
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For western analysis, cells were washed twice with Phosphate Buffer Saline (150 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, and 1.4 mM KH2PO4) and were treated with lysis buffer (10 mM NaCl, 10 mM MgCl2, 10 mM Tris-HCl (pH 7.5), 1% Triton X-100, 1% sodium deoxycholate, Aprotinin 1 μg/ml, Leupeptins 1 μg/ml, Pepstatin A 1 μg/ml, PMSF 100 μg/ml). After 1 minute of incubation on ice the extract was cleared by 1 min. centrifugation at max speed in a microcentrifuge at 4°C. Where indicated, to preserve nucleus integrity and minimize the presence of nuclear material in the extract, the detergents in the lysis buffer (1% Triton X-100, 1% sodium deoxycholate) were replaced by 0.05% NP-40.
Proteins were separated on 12% SDS poliacrylamide gel and transferred on PVDF membrane and incubated with a mouse monoclonal antibody specific for RPS19 (10) 
Immunofluorescence microscopy
Cells were fixed with paraformaldehyde 4%, permeabilized for 5 min in 0.1'% Triton X-100 and incubated with anti-Flag, anti-RPS19 and anti-nucleolin (C23) (Santa Cruz, sc-13057) antibodies.
Secondary antibody was FITC-and TRITC-conjugated and nuclei were stained with Hoechst 33258 (Sigma, not shown). The images were acquired using a confocal laser scanning microscope (LSM 510 Zeiss).
Extract fractionation
For sucrose gradient fractionation, cytoplasmatic extracts, prepared as described above, were layered onto 5%-65% linear gradient containing 30 mM Tris-HCl (pH 7.5), 100 mM NaCl, and 10 mM MgCl2 and centrifuged for 3h at 37,000 rpm in a Beckman SW41 rotor. Twelve fractions were collected while monitoring the absorbance at 260 nm. Proteins from each fraction were precipitated 14 at Pennsylvania State University on http://hmg.oxfordjournals.org/ Downloaded from with 10% TCA. The pellet was washed with acetone, dried, and resuspended in SDS-PAGE Loading Buffer (63 mM Tris-HCl pH 6.8, 5% Glycerol, 1% SDS, 2.5% bromophenol-blue) .
The first five fraction (polysome) were pooled and loaded entirely on a single well whereas only part (1/10) of fraction 11 and 12 was loaded on the gel.
For ribosome isolation 1 ml of cytoplasmic extract was layered onto 1 ml of 15% sucrose, 30 mM Tris-HCl (pH 7.5), 100 mM NaCl, 10 mM MgCl2 and centrifuged in a Beckman type 70.1 rotor for 90 minutes at 100,000 g. The pellet (P, ribosomal fraction) was resuspended directly in SDS-PAGE Loading Buffer. The supernatant (S, free cytoplasmic proteins) was precipitated with 10% TCA and the pellet, washed with acetone, was resuspended in SDS-PAGE Loading Buffer. The proteins were then analyzed by Western blot. and C23. The images were acquired using the confocal microscope at 100X magnification except the "WT stable" sample that was at 63X. constructs were treated with MG132 and extracts were fractionated as in Fig. 3C . Proteins from the pellet (P) and supernatant (S) were analyzed by western blot with antibodies specific for Flag and RPS19. Signals relative to endogenous RPS19 and Flag-RPS19 are indicated. 
